OR WAIT null SECS
July 13, 2024
Thermo Fisher will add Olink to its Life Sciences Solutions business.
July 12, 2024
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
July 10, 2024
The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.
July 04, 2024
LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.
July 02, 2024
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.
June 29, 2024
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
June 28, 2024
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
June 18, 2024
The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.
June 14, 2024
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.
June 11, 2024
Syntegon will expand its processing and packaging by acquiring the Spanish equipment supplier.